Amgen announces the EMA acceptance of kyprolis® marketing authorisation application
Amgen and its subsidiary Onyx Pharmaceuticals, Inc., announced that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) of Kyprolis® (carfilzomib) for injection for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy. The MAA has been granted accelerated assessment by the EMA.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Other conferences & symposia Oncology Patient care carfilzomib EMA Latest News multiple myeloma Source Type: news
More News: Cancer & Oncology | Conferences | Drugs & Pharmacology | European Medicines Agency (EMA) | Marketing | Myeloma